| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
897 Stock Overview
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicine, western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.30 |
| 52 Week High | HK$0.51 |
| 52 Week Low | HK$0.28 |
| Beta | 1.03 |
| 1 Month Change | -3.18% |
| 3 Month Change | -10.29% |
| 1 Year Change | -17.57% |
| 3 Year Change | 22.49% |
| 5 Year Change | -15.28% |
| Change since IPO | -100.00% |
Recent News & Updates
Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now
CEO Ching Ho Tang has done a decent job of delivering relatively good performance at Wai Yuen Tong Medicine Holdings...
Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Shareholder Returns
| 897 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.7% | -0.2% | -0.2% |
| 1Y | -17.6% | -23.1% | -16.2% |
Return vs Industry: 897 exceeded the Hong Kong Pharmaceuticals industry which returned -20.6% over the past year.
Return vs Market: 897 underperformed the Hong Kong Market which returned -16% over the past year.
Price Volatility
| 897 volatility | |
|---|---|
| 897 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in HK Market | 13.2% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 897 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 897's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 1,825 | Ching Ho Tang | https://www.wyth.net |
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicine, western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally. The company offers Chinese medicines and health food products under the Wai Yuen Tong brand name; and western pharmaceutical and personal care products under the Madame Pearl’s and Pearl’s brands. It also engages in the investment, holding, and selling of properties; provision of financial services; and agricultural produce exchange market operation.
Wai Yuen Tong Medicine Holdings Fundamentals Summary
| 897 fundamental statistics | |
|---|---|
| Market Cap | HK$375.65m |
| Earnings (TTM) | -HK$134.97m |
| Revenue (TTM) | HK$1.26b |
0.3x
P/S Ratio-2.8x
P/E RatioIs 897 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 897 income statement (TTM) | |
|---|---|
| Revenue | HK$1.26b |
| Cost of Revenue | HK$709.63m |
| Gross Profit | HK$545.47m |
| Expenses | HK$680.44m |
| Earnings | -HK$134.97m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 43.46% |
| Net Profit Margin | -10.75% |
| Debt/Equity Ratio | 45.4% |
How did 897 perform over the long term?
See historical performance and comparisonValuation
Is Wai Yuen Tong Medicine Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 897 (HK$0.31) is trading below our estimate of fair value (HK$0.79)
Significantly Below Fair Value: 897 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 897 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Pharmaceuticals industry average.
PE vs Market: 897 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 897's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 897 is good value based on its PB Ratio (0.1x) compared to the HK Pharmaceuticals industry average (1.1x).
Future Growth
How is Wai Yuen Tong Medicine Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
8.9%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wai Yuen Tong Medicine Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Wai Yuen Tong Medicine Holdings performed over the past 5 years?
10.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 897 is currently unprofitable.
Growing Profit Margin: 897 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 897 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare 897's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 897 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.8%).
Return on Equity
High ROE: 897 has a negative Return on Equity (-4.47%), as it is currently unprofitable.
Financial Health
How is Wai Yuen Tong Medicine Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 897's short term assets (HK$3.3B) exceed its short term liabilities (HK$2.4B).
Long Term Liabilities: 897's short term assets (HK$3.3B) exceed its long term liabilities (HK$1.6B).
Debt to Equity History and Analysis
Debt Level: 897's net debt to equity ratio (27.4%) is considered satisfactory.
Reducing Debt: 897's debt to equity ratio has increased from 28.4% to 45.4% over the past 5 years.
Debt Coverage: 897's debt is not well covered by operating cash flow (10.6%).
Interest Coverage: 897's interest payments on its debt are not well covered by EBIT (1x coverage).
Balance Sheet
Dividend
What is Wai Yuen Tong Medicine Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 897's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 897's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 897's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 897's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 897 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 897's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.1yrs
Average management tenure
CEO
Ching Ho Tang (59 yo)
3.75yrs
Tenure
HK$8,178,000
Compensation
Mr. Ching Ho Tang, GBS, SBS, JP is Chairman of China Agri-Products Exchange Limited since February 8, 2021. Mr. Tang Co-founded Wang On Group Ltd., in 1987 and served as its Managing Director. Mr. Tang was...
CEO Compensation Analysis
Compensation vs Market: Ching Ho's total compensation ($USD1.05M) is above average for companies of similar size in the Hong Kong market ($USD233.34K).
Compensation vs Earnings: Ching Ho's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: 897's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
Experienced Board: 897's board of directors are seasoned and experienced ( 15.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Wai Yuen Tong Medicine Holdings Limited's employee growth, exchange listings and data sources
Key Information
- Name: Wai Yuen Tong Medicine Holdings Limited
- Ticker: 897
- Exchange: SEHK
- Founded: 1897
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$375.651m
- Shares outstanding: 1.23b
- Website: https://www.wyth.net
Number of Employees
Location
- Wai Yuen Tong Medicine Holdings Limited
- Skyline Tower
- Suite 3101, 31st Floor
- Kowloon Bay
- Kowloon
- Hong Kong
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/19 15:38 |
| End of Day Share Price | 2022/01/19 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.